Method for detecting delta haemolysin of Staphylococcus aureus by mass spectrometry directly using a bacterial population

Patent metadata

Field	Value
Publication number	US-9382571-B2
Application number	US-201214355668-A
Country	US
Kind code	B2
Filing date	Nov 6, 2012
Priority date	Nov 8, 2011
Publication date	Jul 5, 2016
Grant date	Jul 5, 2016

Abstract

The present invention relates to a method for studying a sample containing a bacterial population of Staphylococcus aureus with a specific mass spectrometry technique allowing specific detection on the obtained mass spectrum of the presence or of the absence of a peak at an m/z value of 3005±5 Th Thomson or at 3035±5 Th Thomson, and accordingly, to the issuance of a decision conditioned by this result.

First claim

The invention claimed is:

1. A method for studying a sample containing a bacterial population of Staphylococcus aureus by a mass spectrometry technique comprising the following steps:
a) placing the sample in contact with the medium allowing ionization by action of a laser beam of the molecules present in the sample,
b) ionizing the molecules present in the sample by means of a laser beam,
c) accelerating the ionized molecules obtained by a potential difference,
d) letting the ionized and accelerated molecules freely move in at least one tube under reduced pressure,
e) detecting at least one portion of the ionized and accelerated molecules which have freely moved, so as to measure the time they took for covering at least one tube under reduced pressure and for obtaining a signal corresponding to the number of detected ionized molecules at a given instant,
f) calculating the mass over charge ratio [m/z] of the detected molecules, so as to obtain a signal corresponding to the number of ionized molecules of a same mass over charge ratio [m/z], depending on the m/z ratio of the detected molecules,
g) determining either directly or indirectly whether the ionized molecules obtained in step b), there were or not ionized molecules of a mass/charge ratio [m/z] equal to 3005±5 Th or equal to 3035±5 Th,
h) issuing a decision conditioned by the results obtained in step g).

2. The method according to claim 1 , characterized in that step h) corresponds to a step of correlation of the absence of both ionized molecules with m/z equal to 3005±5 Th and ionized molecules of m/z equal to 3035±5 Th with the absence of hemolysin 6 and of its variant G10S in the analyzed bacterial population of Staphylococcus aureus.

3. The method according to claim 1 , characterized in that the step h) corresponds to a step of correlation of the absence of both ionized molecules with m/z equal to 3005±5 Th and ionized molecules of m/z equal to 3035±5 Th with a dysfunction of the agr (<<Accessory Gene Regulator>>) system in the analyzed bacterial population of Staphylococcus aureus.

4. The method according to claim 1 , characterized in that the analyzed bacterial population of Staphylococcus aureus comes from a biological sample from a patient and in that step h) corresponds to a step for correlation of the absence of both ionized molecules with m/z equal to 3005±5 Th and ionized molecules of m/z equal to 3035±5 Th with issuance for said patient of a clinical diagnostic known to be related to the dysfunction of the agr system.

5. The method according to claim 1 , characterized in that the analyzed bacterial colony of Staphylococcus aureus stems from a biological sample from a patient and in that step h) corresponds to a step for correlation of the absence of both ionized molecules with m/z equal to 3005±5 Th and ionized molecules of m/z equal to 3035±5 Th with the diagnostic of a chronic infection in a patient.

6. The method according to claim 1 , characterized in that step h) corresponds to a step for correlation of the absence of both ionized molecules of m/z equal to 3005±5 Th and ionized molecules of m/z equal to 3035±5 Th with a classification of the analyzed bacterial Staphylococcus aureus population as having the risk of exhibiting reduced sensitivity to glycopeptides (i.e. GISA).

7. The method according to claim 1 , characterized in that mass spectrometry is carried out on a sample containing a population from 10 to 10 9 bacteria, and preferably from 10 5 to 10 6 bacteria.

8. The method according to claim 1 , characterized in that the mass spectrometry used is mass spectrometry (MS) with matrix-assisted desorption-ionization and measurement of the time of flight (MALDI-TOF).

9. The method according to claim 8 characterized in that the determination of step g) is directly inferred from the presence on the obtained mass spectrum of a peak with an m/z value equal to 3005±5 Thor to 3035±5 Th or from the absence of peaks both at 3005±5 Th and at 3035±5 Th.

10. The method according to claim 1 , characterized in that the mass spectrometry used is MALDI TOF/TOF mass spectrometry.

11. The method according to claim 10 , characterized in that in step d), the ionized molecules are left to move in a first tube under reduced pressure, the ions with an m/z mass equal to 3005±5 Th and/or with a m/z mass equal to 3035±5 Th are selected, the ionized molecules after their fragmentation are again accelerated, and the, either fragmented or not, ionized molecules are left to freely move in a second tube.

12. The method according to claim 10 , characterized in that the determination of step g) is indirectly inferred from the presence of at least five fragments from the following ion fragments y and b:
the ion fragments y with masses 147.113, 275.208, 376.255, 523.324, 651.419, 765.462, 864.530, 965.578, 1080.605, 1193.689, 1306.773, 1492.852, 1620.947, 1720.016, 1833.100, 1948.127, 2005.148, 2118.232, 2219.280, 2306.312, 2419.396, 2532.480, 2647.507, 2775.565, 2846.603 and 2976.635; and ion fragments b of masses 131.040, 202.077, 330.136, 445.163, 558.247, 671.331, 758.363, 859.410, 972.494, 1029.516, 1144.543, 1257.627, 1356.695, 1484.790, 1670.870, 1783.954, 1897.038, 2012.065, 2113.112, 2212.181, 2326.224, 2454.319, 2601.387, 2702.435, 2830.530 and 2958.625, with a tolerance of ±1.5 Th, for the peak at 3005±5 Th, and/or
the ion fragments y of masses 147.113, 275.208, 376.255, 523.324, 651.419, 765.462, 864.530, 965.578, 1080.605, 1193.689, 1306.773, 1492.852, 1620.947, 1720.016, 1833.100, 1948.127, 2035.159, 2148.243, 2249.290, 2336.322, 2449.406, 2562.491, 2677.517, 2805.576, 2876.613 and 3006.646; and the ion fragments b of masses 131.040, 202.077, 330.136, 445.163, 558.247, 671.331, 758.363, 859.410, 972.494, 1059.526, 1174.553, 1287.638, 1386.706, 1514.801, 1700.880, 1813.964, 1927.048, 2042.075, 2143.123, 2242.191, 2356.234, 2484.329, 2631.398, 2732.445, 2860.540 and 2988.635, with a tolerance of ±1.5 Th, for the peak at 3035±5 Th.

13. The method according to claim 1 , characterized in that the medium with which the sample is put into contact corresponds to a matrix suitable for MALDI MS deposited on a target, and in that the method includes before step b), the obtaining of crystallization of the matrix on or in which the molecules of the sample are adsorbed.

14. The method according to claim 13 , characterized in that the matrix contains a compound selected from 3,5-dimethoxy-4-hydroxycinnamic acid, α-cyano-4-hydroxycinnamic acid, ferulic acid and 2,5-dihydroxybenzoic acid.

Assignees

• Vandenesch Francois
• Dauwalder Olivier
• Charrier Jean-Philippe
• Welker Martin
• Biomerieux Sa
• Hospices Civils Lyon
• Univ Claude Bernard Lyon

Inventors

• Vandenesch Francois
• Dauwalder Olivier
• Charrier Jean-Philippe
• Welker Martin

Classifications

• H01J49/004

  Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn · CPC title

• C12Q1/14 Primary

  Streptococcus; Staphylococcus · CPC title

• H01J49/40

  Time-of-flight spectrometers (H01J49/36 takes precedence) · CPC title

• G01N2560/00

  Chemical aspects of mass spectrometric analysis of biological material · CPC title

• H01J49/164

  Laser desorption/ionisation, e.g. matrix-assisted laser desorption/ionisation [MALDI] (sample holders H01J49/0418) · CPC title